Search

Your search keyword '"Muccio, Vittorio Emanuele"' showing total 14 results
Start Over Author "Muccio, Vittorio Emanuele"
14 results on '"Muccio, Vittorio Emanuele"'

2. Aberrant Platelet Aggregation as Initial Presentation of Essential Thrombocythemia: Failure of Entero-Coated Aspirin to Reduce Platelet Hyperactivation.

Author

Morotti, Alessandro, Barale, Cristina, Sornatale, Michele, Giugliano, Emilia, Muccio, Vittorio Emanuele, Frascaroli, Chiara, Pautasso, Marisa, Fornari, Alessandro, and Russo, Isabella

Subjects
BLOOD platelet aggregation, ASPIRIN, BLOOD platelets, BONE marrow examination, THROMBOCYTOSIS, THROMBIN receptors, PLATELET aggregation inhibitors, THROMBOPOIETIN receptors
Abstract

Essential thrombocythemia (ET) is a myeloproliferative neoplasm variant characterized by excessive production of platelets. Since the most common cause of mortality and morbidity in ET patients is thrombosis, the excessive production of platelets may cause thrombotic events. However, little is known about the function of platelets in ET. We report a female patient who presented as asymptomatic, without a remarkable medical history, and ET was diagnosed after an incidental finding of moderate thrombocytosis. Notably, together with thrombocytosis, an abnormal platelet phenotype was found for the presence of a massive, rapid and spontaneous formation of aggregates and platelet hypersensitivity to subthreshold concentrations of aggregating agonists. Bone marrow histopathological examination and genetic analysis with the JAK2 (V617F) gene mutation findings confirmed the initial suspicion of ET. Although the ET patient was placed on aspirin, the persistence of the platelet hyperactivation and hyperaggregability prompted a switch in antiplatelet medication from entero-coated (EC) to plain aspirin. As result, platelet hypersensitivity to agonists and spontaneous aggregation were no longer found. Collectively, our study demonstrates that platelet function analysis could be a reliable predictor of ET and that plain aspirin should be preferred over EC aspirin to attenuate platelet hyperreactivity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Predictive Model of Early Relapse in Newly Diagnosed Multiple Myeloma: Analysis from a Pooled Dataset

Author

Zaccaria, Gian Maria, primary, Capra, Andrea, additional, Petrucci, Maria Teresa, additional, Offidani, Massimo, additional, Montefusco, Vittorio, additional, Di Raimondo, Francesco, additional, Bernardini, Annalisa, additional, Liberati, Anna Marina, additional, Omedé, Paola, additional, Mannina, Donato, additional, Caravita di Toritto, Tommaso, additional, Muccio, Vittorio Emanuele, additional, Cascavilla, Nicola, additional, Montani, Stefania, additional, Patriarca, Francesca, additional, Benevolo, Giulia, additional, Saraci, Elona, additional, Belotti, Angelo, additional, Gaidano, Gianluca, additional, Specchia, Giorgina, additional, Nagler, Arnon, additional, Hajek, Roman, additional, Spencer, Andrew, additional, Sonneveld, Pieter, additional, Boccadoro, Mario, additional, and Gay, Francesca, additional

Published
2019
Full Text
View/download PDF

5. Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patients' Characteristics

Author

Muccio, Vittorio Emanuele, primary, Gilestro, Milena, additional, Saraci, Elona, additional, Capra, Andrea, additional, Costa, Alessandro, additional, Ruggeri, Marina, additional, Caltagirone, Simona, additional, Oddolo, Daniela, additional, Mussatto, Chiara, additional, Musto, Pellegrino, additional, Pantani, Lucia, additional, Pavone, Vincenzo, additional, Ronconi, Sonia, additional, Vincelli, Iolanda Donatella, additional, Cafro, Anna Maria, additional, Cellini, Claudia, additional, Innao, Vanessa, additional, Piro, Eugenio, additional, Gay, Francesca, additional, Boccadoro, Mario, additional, and Omedé, Paola, additional

Published
2019
Full Text
View/download PDF

6. Minimal residual disease by flow cytometry and allelic‐specific oligonucleotide real‐time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis

Author

Gambella, Manuela, primary, Omedé, Paola, additional, Spada, Stefano, additional, Muccio, Vittorio Emanuele, additional, Gilestro, Milena, additional, Saraci, Elona, additional, Grammatico, Sara, additional, Larocca, Alessandra, additional, Conticello, Concetta, additional, Bernardini, Annalisa, additional, Gamberi, Barbara, additional, Troia, Rossella, additional, Liberati, Anna Marina, additional, Offidani, Massimo, additional, Rocci, Alberto, additional, Palumbo, Antonio, additional, Cavo, Michele, additional, Sonneveld, Pieter, additional, Boccadoro, Mario, additional, and Oliva, Stefania, additional

Published
2018
Full Text
View/download PDF

7. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.

Author

Gambella, Manuela, Omedé, Paola, Spada, Stefano, Muccio, Vittorio Emanuele, Gilestro, Milena, Saraci, Elona, Grammatico, Sara, Larocca, Alessandra, Conticello, Concetta, Bernardini, Annalisa, Gamberi, Barbara, Troia, Rossella, Liberati, Anna Marina, Offidani, Massimo, Rocci, Alberto, Palumbo, Antonio, Cavo, Michele, Sonneveld, Pieter, Boccadoro, Mario, and Oliva, Stefania

Subjects
POLYMERASE chain reaction, REVERSE transcriptase polymerase chain reaction, FLOW cytometry, OLIGONUCLEOTIDE synthesis, ONCOLOGY, MULTIPLE myeloma, PROGRESSION-free survival
Abstract

Background: Minimal residual disease (MRD) is one of the most relevant prognostic factors in patients with multiple myeloma (MM); however, the impact of maintenance therapy on MRD levels remains unclear. Among patients with newly diagnosed MM (NDMM) who received lenalidomide maintenance until they developed disease progression, the role of MRD status as a predictor of progression-free survival (PFS) was evaluated by multiparameter flow cytometry (MFC) and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction (ASO-RQ-PCR) analysis.Methods: Seventy-three patients with NDMM enrolled in the RV-MM-EMN-441 (clinical trials.gov identifier, NCT01091831) and RV-MM-COOP-0556 (clinicaltrials.gov identifier, NCT01208766; European Myeloma Network EMN02/HO95 MM Trial) phase 3 trials who achieved at least a very good partial response after intensification/consolidation were included. The median patient age was 57 years (interquartile range, 53-61 years), and all patients received lenalidomide maintenance until they developed progression. MRD was evaluated on bone marrow after intensification/consolidation, after 6 courses of maintenance, and every 6 months thereafter until clinical relapse using both ASO-RQ-PCR (sensitivity, 10-5 ) and MFC (sensitivity, from 10-4 to 10-5 ).Results: After intensification/consolidation, 33 of 72 patients (46%) achieved a molecular complete response (m-CR), and 44 of 70 (63%) achieved a flow complete response (flow-CR). Almost 27% of patients who were MRD-positive after consolidation became MRD-negative during maintenance. After a median follow-up of 38 months, PFS was prolonged in patients who achieved negative MRD status during maintenance according to results from both ASO-RQ-PCR analysis (hazard ratio, 0.29; 95% confidence interval, 0.14-0.62; P = .0013) and MFC (hazard ratio, 0.19; 95% confidence interval, 0.09-0.41; P < .001). The impact of negative MRD status on PFS was similar in all subgroups (ASCT and no-ASCT; International Staging System stages I, II, and III; high-risk and standard-risk cytogenetics), and the two techniques were highly correlated.Conclusions: MRD status is a stronger predictor of PFS than standard risk factors, and lenalidomide maintenance further increases the rate of negative MRD results. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

8. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis

Author

Oliva, Stefania, primary, Gambella, Manuela, additional, Gilestro, Milena, additional, Muccio, Vittorio Emanuele, additional, Gay, Francesca, additional, Drandi, Daniela, additional, Ferrero, Simone, additional, Passera, Roberto, additional, Pautasso, Chiara, additional, Bernardini, Annalisa, additional, Genuardi, Mariella, additional, Patriarca, Francesca, additional, Saraci, Elona, additional, Petrucci, Maria Teresa, additional, Pescosta, Norbert, additional, Liberati, Anna Marina, additional, Caravita, Tommaso, additional, Conticello, Concetta, additional, Rocci, Alberto, additional, Musto, Pellegrino, additional, Boccadoro, Mario, additional, Palumbo, Antonio, additional, and Omedè, Paola, additional

Published
2016
Full Text
View/download PDF

9. Minimal Residual Disease Detection By Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: A Preliminary Analysis of the EMN02/HO95 MM Study

Author

Oliva, Stefania, primary, Gambella, Manuela, additional, Gilestro, Milena, additional, Gay, Francesca, additional, Larocca, Alessandra, additional, Liberati, Anna Marina, additional, Bonello, Francesca, additional, Benevolo, Giulia, additional, Ciccone, Giovannino, additional, Caravita, Tommaso, additional, Muccio, Vittorio Emanuele, additional, Caltagirone, Simona, additional, Spada, Stefano, additional, Gamberi, Barbara, additional, Ferrero, Simone, additional, Ruggeri, Marina, additional, Rossi, Giuseppe, additional, Saraci, Elona, additional, Offidani, Massimo, additional, Petrucci, Maria Teresa, additional, Boccadoro, Mario, additional, Sonneveld, Pieter, additional, Palumbo, Antonio, additional, and Omedè, Paola, additional

Published
2015
Full Text
View/download PDF

10. Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents

Author

Muccio, Vittorio Emanuele, primary, Saraci, Elona, additional, Gilestro, Milena, additional, Gattei, Valter, additional, Zucchetto, Antonella, additional, Astolfi, Monica, additional, Ruggeri, Marina, additional, Marzanati, Eleonora, additional, Passera, Roberto, additional, Palumbo, Antonio, additional, Boccadoro, Mario, additional, and Omedè, Paola, additional

Published
2015
Full Text
View/download PDF

11. In Multiple Myeloma, Minimal Residual Disease (MRD) Is an Early Predictor of Progression and Is Modulated By Maintenance Therapy with Lenalidomide

Author

Gambella, Manuela, primary, Omedè, Paola, additional, Oliva, Stefania, additional, Gilestro, Milena, additional, Muccio, Vittorio Emanuele, additional, Drandi, Daniela, additional, Ferrero, Simone, additional, Gay, Francesca, additional, Patriarca, Francesca, additional, Palladino, Carmela, additional, Petrucci, Maria Teresa, additional, Pescosta, Norbert, additional, Liberati, Anna Marina, additional, Caravita, Tommaso, additional, Di Raimondo, Francesco, additional, Rocci, Alberto, additional, Musto, Pellegrino, additional, Boccadoro, Mario, additional, and Palumbo, Antonio, additional

Published
2014
Full Text
View/download PDF

12. Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma

Author

Palumbo, Antonio, primary, Larocca, Alessandra, additional, Montefusco, Vittorio, additional, Rossi, Davide, additional, Carella, Angelo Michele, additional, Mina, Roberto, additional, Crippa, Claudia, additional, Sciacca, Mariella, additional, Galli, Monica, additional, Scalabrini, Delia Rota, additional, Marcatti, Magda, additional, Guglielmelli, Tommasina, additional, Giuliani, Nicola, additional, La Verde, Giacinto, additional, Baldi, Ileana, additional, Muccio, Vittorio Emanuele, additional, Boccadoro, Mario, additional, and Corradini, Paolo, additional

Published
2012
Full Text
View/download PDF

14. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.

Author

Oliva S, Gambella M, Gilestro M, Muccio VE, Gay F, Drandi D, Ferrero S, Passera R, Pautasso C, Bernardini A, Genuardi M, Patriarca F, Saraci E, Petrucci MT, Pescosta N, Liberati AM, Caravita T, Conticello C, Rocci A, Musto P, Boccadoro M, Palumbo A, and Omedè P

Subjects
Antineoplastic Combined Chemotherapy Protocols therapeutic use, Consolidation Chemotherapy, Disease Progression, Female, Humans, Lenalidomide, Maintenance Chemotherapy, Male, Middle Aged, Multiple Myeloma genetics, Multiple Myeloma pathology, Neoplasm, Residual, Prospective Studies, Thalidomide administration & dosage, Thalidomide therapeutic use, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Biomarkers, Tumor genetics, Multiple Myeloma therapy, Thalidomide analogs & derivatives, Transplantation, Autologous methods
Abstract

We analyzed 50 patients who achieved at least a very good partial response in the RV-MM-EMN-441 study. Patients received consolidation with autologous stem-cell transplantation (ASCT) or cyclophosphamide-lenalidomide-dexamethasone (CRD), followed by Lenalidomide-based maintenance. We assessed minimal residual disease (MRD) by multi-parameter flow cytometry (MFC) and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction (ASO-RQ-PCR) after consolidation, after 3 and 6 courses of maintenance, and thereafter every 6 months until progression. By MFC analysis, 19/50 patients achieved complete response (CR) after consolidation, and 7 additional patients during maintenance. A molecular marker was identified in 25/50 patients, 4/25 achieved molecular-CR after consolidation, and 3 additional patients during maintenance. A lower MRD value by MFC was found in ASCT patients compared with CRD patients (p=0.0134). Tumor burden reduction was different in patients with high-risk vs standard-risk cytogenetics (3.4 vs 5.2, ln-MFC; 3 vs 6 ln-PCR, respectively) and in patients who relapsed vs those who did not (4 vs 5, ln-MFC; 4.4 vs 7.8 ln-PCR). MRD progression anticipated clinical relapse by a median of 9 months while biochemical relapse by a median of 4 months. MRD allows the identification of a low-risk group, independently of response, and a better characterization of the activity of treatments.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results